Gufic Biosciences Limited AI Stock Analysis
Want to see IN:GUFICBIO full AI Analyst Report?
Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis
Gufic Biosciences Limited
(NSE:GUFICBIO)
Moderate financial performance driven by balance sheet strength but offset by profit declines and cash volatility is the primary factor; bullish technical momentum provides support while high valuation weighs on the score.
Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 42.18B
- Dividend Yield
- 0.02%
- Average Volume (3M)
- 6,617
- Price to Earnings (P/E)
- 57.7
- Beta (1Y)
- 0.64
- Revenue Growth
- 16.70%
- EPS Growth
- 18.73%
- Country
- India
- Employees
- 1,491
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Gufic Biosciences Limited Business Overview & Revenue Model
Company Description
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifunga...
Gufic Biosciences Limited Financial Statement Overview
Summary
Solid balance sheet growth and manageable debt provide stability, but declining profitability, margin compression, and cash flow volatility pose risks.
Income Statement
55NeutralBalance Sheet
75PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.81B | 9.44B | 8.20B | 8.07B | 6.91B | 7.79B |
| Gross Profit | 4.52B | 3.40B | 2.97B | 4.07B | 3.51B | 3.56B |
| EBITDA | 1.66B | 1.54B | 1.38B | 1.48B | 1.37B | 1.50B |
| Net Income | 734.57M | 642.15M | 696.50M | 861.36M | 797.05M | 958.40M |
Balance Sheet | ||||||
| Total Assets | 0 | 13.42B | 11.69B | 10.93B | 8.61B | 5.21B |
| Cash, Cash Equivalents and Short-Term Investments | 621.86M | 762.17M | 290.22M | 11.37M | 286.02M | 116.08M |
| Total Debt | 0 | 4.05B | 3.36B | 3.33B | 3.34B | 643.87M |
| Total Liabilities | -6.65B | 6.77B | 5.68B | 5.60B | 5.13B | 2.52B |
| Stockholders Equity | 6.65B | 6.65B | 6.01B | 5.33B | 3.48B | 2.69B |
Cash Flow | ||||||
| Free Cash Flow | 434.82M | -180.11M | 270.96M | -1.20B | -2.14B | 187.86M |
| Operating Cash Flow | 591.15M | 131.71M | 1.03B | -74.57M | -265.87M | 1.06B |
| Investing Cash Flow | -152.90M | -319.73M | -717.09M | -1.02B | -1.91B | -945.89M |
| Financing Cash Flow | 150.53M | 652.67M | -163.26M | 823.81M | 2.34B | -62.44M |
Gufic Biosciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 424.10 is below the 20-day moving average (MA) of 429.64, below the 50-day MA of 426.47, and above the 200-day MA of 360.43, indicating a neutral trend. The MACD of 8.45 indicates Negative momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 36.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.
Gufic Biosciences Limited Peers Comparison
Overall Rating
IN:BLISSGVS65Neutral
IN:GUFICBIO61Neutral
IN:MOREPENLAB55Neutral
IN:ORCHPHARMA55Neutral
IN:UNICHEMLAB51Neutral
IN:INDOCO43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | INR 71.70B | 45.00 | ― | 0.22% | 24.87% | 46.37% | |
| 61Neutral | INR 42.53B | 57.68 | ― | 0.02% | 16.70% | 18.73% | |
| 55Neutral | INR 50.55B | 26.93 | ― | 0.22% | 30.20% | 91.17% | |
| 55Neutral | INR 57.21B | 559.03 | ― | ― | 10.83% | -89.83% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | INR 34.01B | 9.95 | ― | ― | 6.44% | 283.10% | |
| 43Neutral | INR 22.26B | 71.18 | ― | 0.08% | 10.75% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:GUFICBIO | Gufic Biosciences Limited | 424.10 | 70.99 | 20.10% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 674.30 | 515.11 | 323.58% | |
| IN:INDOCO | Indoco Remedies Limited | 241.15 | -16.88 | -6.54% | |
| IN:MOREPENLAB | Morepen Laboratories Limited | 92.25 | 48.31 | 109.96% | |
| IN:ORCHPHARMA | Orchid Pharma Limited | 955.40 | 89.65 | 10.36% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 483.05 | 15.25 | 3.26% |
Gufic Biosciences Limited Corporate Events
Gufic Biosciences Receives USFDA Observations After Pre-Approval Inspection at Indore Plant
Gufic Biosciences Limited has disclosed that the U.S. Food and Drug Administration recently conducted a pre-approval inspection at its manufacturing facility in Indore, Madhya Pradesh, over the period from October 15 to October 23, 2026. The inspecti...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
